P-selectin glycoprotein ligand blocking antibodies
AssigneeThe Board of Regents of the University of Oklahoma
InventorsRichard D. Cummings, Kevin L. Moore, Rodger P. McEver
Life of this patent
Estimating the term…
Abstract
P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of .sup.3 H!glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.
Claims4
An antibody to P-selectin glycoprotein ligand, the glycoprotein ligand comprising a fucosylated sialylated glycoprotein containing sialyl Lewis X antigen and having an apparent relative molecular weight of approximately 120,000 as assessed by SDS-PAGE under reducing condition, and wherein the antibody is effective in specifically blocking the binding of P-selectin to P-selectin glycoprotein ligand.
An antibody to a protein component of P-selectin glycoprotein ligand, the glycoprotein ligand comprising a fucosylated sialylated glycoprotein containing sialyl Lewis X antigen and having an apparent relative molecular weight of approximately 120,000 as assessed by SDS-PAGE under reducing condition, and wherein the antibody is effective in specifically blocking the binding of P-selectin to P-selectin glycoprotein ligand.
Dependencies are inferred from the claim text.